Anti-Obesity Medications Improve Body Composition and Prevent Heart Disease

Obesity is a global epidemic, significantly increasing the risk of cardiovascular disease (CVD), including heart attacks, strokes, and heart failure. Traditionally, weight loss has been the primary focus, but the specific impact of reducing fat mass versus preserving lean muscle mass on long-term cardiovascular outcomes has become increasingly important. This review addresses how modern anti-obesity medications (AOMs) influence body composition and their direct role in preventing cardiovascular disease.

The review consistently highlighted that modern anti-obesity medications (AOMs), including GLP-1 receptor agonists and dual GLP-1/GIP agonists, not only induce significant weight loss but also favorably alter body composition. Specifically, these medications were shown to promote a greater reduction in fat mass relative to lean muscle mass compared to traditional weight loss interventions, often leading to improved muscle preservation. The most significant finding was the robust evidence demonstrating that AOMs lead to substantial improvements in cardiovascular risk factors, including reductions in blood pressure, lipid profiles (e.g., lower triglycerides, higher HDL), and glycemic control, directly contributing to cardiovascular disease prevention. Furthermore, the review underscored the critical importance of preserving muscle mass during weight loss, as this is crucial for metabolic health, strength, and long-term functional capacity, a benefit often observed with newer AOMs. These positive changes in body composition are directly linked to the observed reductions in major adverse cardiovascular events (MACE) across various patient cohorts, showcasing a multifaceted benefit beyond mere weight reduction.